NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

NCT06462014

CompletedN/A

Sponsor: Pfizer

Conditions: Prostate Cancer

Interventions: Relugolix

Countries: United States

The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix

Eligibility overview

Sex: MALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Male with ≥ 1 diagnosis for PC
* Had ≥ 2 prescriptions of relugolix on or after the first observed PC diagnosis.
* Index date: the initiation date of relugolix
* At least 18 years old at the index date

Exclusion Criteria:

* had surgical castration (bilateral orchiectomy) any time before the index date

Locations (1)

New York, New York, United States